Market Place
Sourcing Support
All News #Library
Rare Diseases
EU Approves IMCIVREE for Acquired Hypothalamic Obesity
01 May 2026 //
FIRSTWORD PHARMA
Rhythm Pharma Receives Positive CHMP Opinion for IMCIVREE
26 Mar 2026 //
GLOBENEWSWIRE
Rhythm Pharma Names PANTHERx Rare Exclusive U.S. Specialty
20 Mar 2026 //
PR NEWSWIRE
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity
19 Mar 2026 //
GLOBENEWSWIRE
Rhythm Pharma Reveals Phase 3 EMANATE Trial Topline Results
16 Mar 2026 //
GLOBENEWSWIRE
Rhythm Pharma Reveals More Positive Phase 3 Setmelanotide Data
01 Mar 2026 //
GLOBENEWSWIRE
Rhythm Pharma`s Setmelanotide Effective in Prader-Willi Syndrome
11 Dec 2025 //
GLOBENEWSWIRE
Rhythm Pharma: Setmelanotide Ph 2 Data in Prader-Willi Syndrome
10 Dec 2025 //
GLOBENEWSWIRE
Rhythm Pharma Reveals Four Datasets At Obesityweek Conference
10 Nov 2025 //
GLOBENEWSWIRE
FDA Extends Review For IMCIVREE In Acquired Hypothalamic Obesity
07 Nov 2025 //
GLOBENEWSWIRE
Rhythm Pharma Launches IMCIVREE Reimbursement In Canada
05 Nov 2025 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals to Announce Topline Results from Phase 3
07 Apr 2025 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Reacquires Imcivree® Rights in China
21 Mar 2025 //
GLOBENEWSWIRE
Rhythm Pharma Gets Orphan Drug Status For Setmelanotide In Japan
19 Mar 2025 //
GLOBENEWSWIRE
Rhythm Receives Orphan Drug Designation from EMA for Setmelanotide
19 Sep 2023 //
GLOBENEWSWIRE
FDA Grants Rhythm Rare Pediatric Disease Designation for Rare Obesities Drug
02 Jul 2020 //
GLOBALNEWS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.